Torrent Pharmaceuticals gets observations from USFDA for Dahej plant
8th Apr 2019

Torrent Pharmaceuticals has received certain observations from the US Food and Drug Administration (USFDA) for Dahej plant which are procedural in nature and the company is confident of addressing them satisfactorily. The audit at Dahej Plant of the company was carried out by USFDA in the month of March, 2019.

Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.